UNITED THERAPEUTICS CORPORATION
NASDAQ: UTHR (United Therapeutics Corporation)
Last update: 1 hour ago588.61
6.15 (1.06%)
| Previous Close | 582.46 |
| Volume | 461,356 |
| Price / Earnings (Forward) | 18.46 |
| Price / Sales | 8.18 |
| Price / Book | 3.80 |
| 52 Weeks Range |
| Profit Margin | 40.44% |
| Operating Margin (TTM) | 48.19% |
| Diluted EPS (TTM) | 25.11 |
| Quarterly Revenue Growth (YOY) | 17.20% |
| Quarterly Earnings Growth (YOY) | 5.10% |
| Total Debt/Equity (MRQ) | 2.94% |
| Current Ratio (MRQ) | 5.46 |
| Operating Cash Flow (TTM) | 1.41 B |
| Levered Free Cash Flow (TTM) | 825.79 M |
| Return on Assets (TTM) | 12.93% |
| Return on Equity (TTM) | 19.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | United Therapeutics Corporation | Mixed | Bullish |
AIStockmoo Score
| Value 35% | 4.6 |
| AI Insight info | NA |
| Relative Valuation info | 4.6 |
| Financial Health info | 4.5 |
| Timing 35% | 1.8 |
| AI Technical info | NA |
| Technical Oscillators info | 4.0 |
| Technical Moving Averages info | -1.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | 0.0 |
| Environment | ×0.84 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -6.1% |
| Pillar Agreement | ×1.25 |
| Not in score | |
| Price Volatility info | -2.2 |
| Final Score | 2.32 |
Select this tab to load the latest available analysis.
|
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.75% |
| % Held by Institutions | 100.69% |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ROTHBLATT MARTINE A | - | 595.24 | -47,500 | -28,273,805 |
| Aggregate Net Quantity | -47,500 | |||
| Aggregate Net Value ($) | -28,273,805 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 595.24 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Officer | 03 Nov 2026 | Automatic sell (-) | 9,500 | 601.32 | 5,712,540 |
| ROTHBLATT MARTINE A | Officer | 03 Nov 2026 | Option execute | 9,500 | - | - |
| ROTHBLATT MARTINE A | Officer | 02 Nov 2026 | Automatic sell (-) | 9,500 | 596.13 | 5,663,235 |
| ROTHBLATT MARTINE A | Officer | 02 Nov 2026 | Option execute | 9,500 | - | - |
| ROTHBLATT MARTINE A | Officer | 30 Oct 2026 | Automatic sell (-) | 9,500 | 598.72 | 5,687,840 |
| ROTHBLATT MARTINE A | Officer | 30 Oct 2026 | Option execute | 9,500 | - | - |
| ROTHBLATT MARTINE A | Officer | 29 Oct 2026 | Automatic sell (-) | 9,500 | 593.54 | 5,638,630 |
| ROTHBLATT MARTINE A | Officer | 29 Oct 2026 | Option execute | 9,500 | - | - |
| ROTHBLATT MARTINE A | Officer | 28 Oct 2026 | Automatic sell (-) | 9,500 | 586.48 | 5,571,560 |
| ROTHBLATT MARTINE A | Officer | 28 Oct 2026 | Option execute | 9,500 | - | - |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |